DelveInsight’s “Congestive Heart Failure (Chronic Heart Failure) Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Chronic Heart Failure, historical and forecasted epidemiology as well as the Chronic Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Chronic Heart Failure market report provides current treatment practices, emerging drugs, Chronic Heart Failure market share of the individual therapies, and current and forecasted Chronic Heart Failure market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chronic Heart Failure treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Some of the key facts of the Congestive Heart Failure Market Report:
- As per the estimates, there were 155,410, 258,156, 719,222, 1,187,517, 1,607,918 and 1,234,895 cases of
- There are major Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others. Amongst them in 2020, in the US, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease and Dilated cardiomyopathy which is further expected to increase during the study period (2018-2030).
- As per the DelveInsight analysis, the total prevalent cases of Heart Failure were found to be 2,955,330 cases in 2020 in Germany which might increase during the study period (2018-2030).
Key benefits of the Congestive Heart Failure Market report:
- The report covers the descriptive overview of Chronic Heart Failure, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Chronic Heart Failure epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Heart Failure is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Chronic Heart Failure market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Heart Failure market
Got queries? Click here to know more about the Congestive Heart Failure Market Landscape
Congestive Heart Failure Overview
Heart Failure (HF) is also known as congestive heart failure. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes shortness of breath and fatigue (tiredness) and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck. The signs and symptoms of HF are subtle at the initial stage, and these are generally misguided for common signs of aging. The common symptoms of HF are because of extra fluid or congestion which leads to blocking of the vessels. The starting of the congestion in the lungs is carried forward to the different parts of the body. At later stages of the disease, the cardiac output reduces.
Congestive Heart Failure Epidemiological Insight
- As per the DelveInsight analysis, the total prevalent cases of Heart Failure were found to be 2,955,330 cases in 2020 in Germany which might increase during the study period (2018-2030).
- As per the DelveInsight analysis, the total prevalent cases of HF in Japan were found to be 1,178,678 cases in 2020. The total diagnosed prevalent cases of HF in Japan were found to be 884,008 cases in 2020 which are expected to increase during the study period.
- As per Delveinsight analysis, there were 548,085 and 335,923 diagnosed prevalent cases of HF with preserved (and medium) and reduced ejection fraction in 2020.
Congestive Heart Failure Epidemiological Segmentation
- Heart Failure Prevalent Population
- Heart FailureGender-specific diagnosed cases
- Heart Failure Age-specific diagnosed cases
- Heart Failure with ejection fraction Diagnosed prevalent cases
- Diagnosed Prevalent cases of Heart Failure associated with comorbidities
Congestive Heart Failure Market Outlook
Heart Failure is generally defined as a complex clinical syndrome categorized by distinct symptoms and signs which is caused by structural and functional cardiac aberrations. However, at present, the common term for describing heart failure is based on left ventricular ejection fraction. Also, HF with normal LVEF (≥ 50%) is known as HFpEF, and HF with decreased LVEF (< 40%) is as HFrEF. HF with a 40–49% middle range is known as heart failure with a mid-range ejection fraction (HFmrEF). But as of recent guidelines, HFmrEF is considered a separate unit, but the epidemiology, treatment, pathophysiology, and prognosis of HFrEF are quite unclear. Currently, the treatment of heart failure is dependent on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Additionally, other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, and nitrates, among others, are used for the treatment of patients affected by heart failure.
Learn more by requesting for sample @ Congestive Heart Failure Market Landscape
Congestive Heart Failure Key Companies
- Otsuka pharmaceuticals
- AstraZeneca
- Applied Therapeutics
- Bayer
- And many others
Congestive Heart Failure Therapies
- OPC- 61815
- AZD 4831
- AT-001
- Rexlemestrocel-L (Revascor)
- And many others
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Congestive Heart Failure
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Congestive Heart Failure Emerging Therapies
- Congestive Heart Failure Market Outlook
- Market Access and Reimbursement of Therapie
- Appendix
- Congestive Heart Failure Report Methodology
- DelveInsight Capabilities
- Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/